Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) BRAF Antibodies:
anti-Human BRAF Antibodies:
anti-Rat (Rattus) BRAF Antibodies:
Go to our pre-filtered search.
Human Polyclonal BRAF Primary Antibody for FACS, WB - ABIN1881118
Hingorani, Jacobetz, Robertson, Herlyn, Tuveson: Suppression of BRAF(V599E) in human melanoma abrogates transformation. in Cancer research 2003
Show all 6 Pubmed References
Human Monoclonal BRAF Primary Antibody for IHC, ELISA - ABIN1724658
Rapp, Goldsborough, Mark, Bonner, Groffen, Reynolds, Stephenson: Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. in Proceedings of the National Academy of Sciences of the United States of America 1983
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody for IHC, ELISA - ABIN965693
Kim, Giuliano, Turner, Gaffney, Umetani, Kitago, Elashoff, Hoon: Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. in Annals of surgery 2006
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody for ICC, IHC - ABIN968991
Di Nicolantonio, Martini, Molinari, Sartore-Bianchi, Arena, Saletti, De Dosso, Mazzucchelli, Frattini, Siena, Bardelli: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008
Show all 2 Pubmed References
Human Polyclonal BRAF Primary Antibody for DB - ABIN389897
Frattini, Ferrario, Bressan, Balestra, De Cecco, Mondellini, Bongarzone, Collini, Gariboldi, Pilotti, Pierotti, Greco: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. in Oncogene 2004
Show all 3 Pubmed References
Human Monoclonal BRAF Primary Antibody for PLA, ELISA - ABIN513800
Liu, Chen, Chau, Jan, Chen, Hsu, Lin, Juang, Lu, Cheng, Chen, Chang, Ting, Kao, Hsiao, Huang: Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma. in Molecular & cellular proteomics : MCP 2013
Human Polyclonal BRAF Primary Antibody for ELISA, IHC (p) - ABIN5573331
Wiggans, Reilly, Kass, Maggs: Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma. in Veterinary ophthalmology 2016
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Xenopus, but exon 8b is present only in eutherians.
Gene expression studies nominated TWIST2 (show TWIST2 Antibodies) as a key effector downstream of BRAF.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Danio rerio, but exon 8b is present only in eutherians.
BRAF activation is sufficient for f-nevus formation, and is among the primary events in melanoma development.
BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.
Using a conditional allele for Braf(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.
This study detected the BrafV637E mutation by whole-exome analysis in 4/4 hepatic tumors induced by neonatal treatment with diethylnitrosamine (DEN) in male B6C3F1 mice.
a critical threshold for inhibition of MAPK (show MAPK1 Antibodies) signaling is required to optimally restore expression of thyroid differentiation genes in thyroid cells and in mice with BrafV600E-induced thyroid cancer.
A- and B-Raf ablation in chondrocytes does not alter skeletal development, whereas ablation of C-Raf decreases hypertrophic chondrocyte apoptosis and impairs vascularization of the growth plate. However, ablation of C-Raf does not impair phosphate-induced ERK1/2 phosphorylation in vitro, but leads to rickets by decreasing VEGF protein stability.
these contrasting signatures precisely match those proposed to confer bias toward Hras (show HRAS Antibodies)(CAA61CTA) versus Braf(GTG636GAG) mutations in the original tumor sets. Our findings highlight a novel mechanism whereby exposure history acts through strand-biased mutagenesis to specify activation of preferred oncogenes
these results suggest that the activation of 5-HT1D receptors selectively enhanced IA via the Gbetagamma of the Go-protein, PKA, and the sequential B-Raf (show SNRPE Antibodies)-dependent p38 MAPK (show MAPK14 Antibodies) signaling cascade.
BRAF V600E inhibition stimulates AMP-activated protein kinase (show PRKAA2 Antibodies)-mediated autophagy in colorectal cancer cells.
these data confirm the existence of a negative feedback pathway by which BRAF protein stability is regulated by ERK (show EPHB2 Antibodies).
coexpression of BRAF(V600E) and KRAS(G12D) in early tumorigenesis leads to negative selection due to oncogene (show RAB1A Antibodies)-induced senescence
findings suggest that targeting ErbB-3 (show ERBB3 Antibodies) receptors could represent an effective therapeutic approach in BRAF-V600E mutant colon cancer
This study is the first to report BRAF mutations in a pure adult sample of differentiated thyroid cancer of Saudi Arabian ethnicity.
No significant impact on prognosis was observed for mutated KRAS, NRAS, and PIK3CA genes or combined RAS mutations
BRAF mutations were not associated with an elevated risk for distant metastasis.
ZNF767-BRAF fusion is associated with mucosal melanomas.
The expression of the nuclear and cytoplasmic forms of p16 (show CDKN2A Antibodies) represent two independent mechanisms, and both seemed to control proliferation in response to oncogenic stimuli, protecting the cell from malignant transformation in BRAF-mutated gastrointestinal stromal tumors.
BRAF mutation is associated with papillary thyroid carcinoma.
BRAF mutation was found to be associated with lymph node metastasis as first metastasis and sentinel lymph node positivity. BRAF and NRAS (show NRAS Antibodies) mutations were associated with CNS and liver metastasis and NRAS (show NRAS Antibodies) mutation with lung metastasis.
The association of BRAF mutations with clinical and pathological features was assessed next in a cohort of 840 KRAS exon 2 wild type CRC (show CALR Antibodies) patients screened with the Real Time PCR assay.
Bromodomain and extra-terminal (BET) inhibitors can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK (show MAPK1 Antibodies) signaling pathway.
findings should encourage the genetic evaluation of BRAF mutation. This study highlights the potential of RCM (show Unc5c Antibodies) as a supplementary tool in the screening of BRAF-mutated melanomas
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.
, serine/threonine protein kinase BRAF
, v-raf murine sarcoma viral oncogene homolog B1
, serine/threonine-protein kinase B-raf
, serine/threonine-protein kinase B-raf-like
, B-Raf proto-oncogene serine/threonine-protein kinase (p94)
, proto-oncogene B-Raf
, sm protein E
, small nuclear ribonucleoprotein E
, 94 kDa B-raf protein
, murine sarcoma viral (v-raf) oncogene homolog B1
, B-raf protein
, B-Raf proto-oncogene serine/threonine-protein kinase
, proto-oncogene c-Rmil
, rmil serine/threonine-protein kinase
, serine/threonine kinase
, serine/threonine-protein kinase Rmil